Global Pancreatic Cancer Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

12/mar/2018 08:53:43 pbi Contatta l'autore

Questo comunicato è stato pubblicato più di 6 mesi fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Pancreatic cancer is the disease characterized by the abnormal proliferation of tumor cells in the pancreas leads to hinder in the pancreas function. Pancreatic cancer is majorly classified into 2 types namely exocrine cancers and neuroendocrine cancers. Symptoms associated with the pancreas cancer include jaundice, weight loss, abdominal pain, and diarrhea. Pancreatic cancer mainly occurs due to the consumption of tobacco and alcohol, smoking, obesity, and family history of pancreatitis. Pancreatic cancer can be diagnosed by using the MRI, CT scan, and ultrasound techniques and can be prevented by chemotherapy, radiotherapy, and surgery.


Increase in the alcohol and tobacco consumption, a rise in the government funding for the R&D activities, growing prevalence of pancreatic cancer diseases, and promising pipeline drugs for the pancreatic cancer treatment are anticipated to propel the pancreatic cancers market growth over the forecast period. Furthermore, rise in obesity population, family history of pancreatitis, huge investment by the companies for the development of newer drugs expected to drive the Global Pancreatic Cancer Therapeutics Market over the forecast period. However, stringent regulatory policies, difficulty in early-stage disease diagnosis, the high cost of the treatment, adverse effects associated with the drugs, and lesser drugs available for the treatment might hamper the growth of Global Pancreatic Cancer Therapeutics Market.


          A sample of this report is available upon request @  


Pancreatic cancer therapeutics market is segmented on the basis of disease type, treatment type, and end user


Based on the treatment type, pancreatic cancer therapeutics market is segmented into the following:

·         Chemotherapy

o    Alkylating agents

o    Anti-metabolites

o    Natural products

o    Others

·         Targeted therapy

·         Others


Based on the disease type, pancreatic cancer therapeutics market is segmented into the following:

·         Exocrine pancreas cancer

·         Exocrine pancreas cancer


Based on the distribution channel, pancreatic cancer therapeutics market is segmented into the following:

·         Hospital pharmacies

·         Retail Pharmacies

·         Online pharmacies


     To view TOC of this report is available upon request @



Pancreatic surgery therapeutics market is growing at a significant CAGR owing to increase in the prevalence of the pancreatic cancer and increase in R&D activities for the innovation of newer therapeutics. Increase in the government funding and huge investments from private sector for R&D activities is anticipated to propel the market growth. Acquisitions & mergers, collaborations, product pipeline are the key factors driving the market players revenue growth in pancreatic cancer therapeutics market. For instance, in December 2015, Boehringer Ingelheim collaborated with MD Andersen Cancer Centre for the development of newer therapeutics for pancreatic cancer. Similarly, in September 2013, Celgene received FDA approval for Abraxane used for the treatment of pancreatic cancer.


  Need more information about this report @ 



Geographically, pancreatic cancer therapeutics market is segmented into the Europe, Latin America, Asia Pacific, Middle East and Africa, and North America. North America pancreatic cancer therapeutics market is growing at significant rate due to increase in the prevalence of pancreatic cancer majorly in U.S. (according to NIH 2014, about 64,668 people diagnosed with pancreatic cancer). In addition, high adoption of pancreatic therapeutics, increase in healthcare expenditure, and rise in R&D activities are propelling the pancreatic cancer therapeutics market in North America. In Europe region, rise in the prevalence of pancreatic cancer majorly in Germany, Finland, Austria, U.K and other Europe countries (according to Cancer Research UK 2014, about 9,600 new pancreatic cancer cases in UK and 8,817 people died of the disease), and developed healthcare infrastructure boost the pancreatic cancer therapeutics market. However, Asia Pacific is an emerging region for pancreatic cancer therapeutics market owing to increase in R&D expenditure rise in geriatric and obese population, growing healthcare expenditure are expected to fuel the market over the forecast period.



Some of the players in pancreatic cancer therapeutics market are F. Hoffmann-La Roche Ltd. (Switzerland), Novartis AG (Switzerland), Merck & Co., Inc. (U.S.), Pfizer, Inc. (U.S.), Eli Lilly and Company (U.S.), Boehringer Ingelheim GmbH (Germany), Celgene Corporation (U.S.), Amgen, Inc. (U.S.), Tempus, Inc. (U.S.), and Ipsen (France) to name a few.



Get access to full summary @

blog comments powered by Disqus è un servizio offerto da Factotum Srl